What is
Fetal Valproate Spectrum Disorder
FVSD can affect each person differently. Some children may have visible physical features or medical problems from birth, while others may not be recognised until later, when difficulties with speech, learning, memory, behaviour, coordination, anxiety, attention or social communication become more apparent. Clinical guidance describes FVSD as involving a pattern of congenital differences, facial features and neurodevelopmental difficulties, including cognitive and social impairments.
Families affected by FVSD often face complex and lifelong challenges. These may include repeated appointments, educational needs, emotional strain, care responsibilities, and the difficulty of having their concerns understood. Many parents report that they knew something was wrong long before they received answers.
Recognition matters. Understanding FVSD helps families access appropriate support, education, health assessments and reasonable adjustments. It also helps professionals listen more carefully to patient histories, especially where there has been prenatal exposure to valproate.
FVSD is not the fault of the child or the family. It is a medicine-related harm that requires compassion, informed care, and proper recognition.
Important: Anyone currently taking valproate should not stop or change their medicine suddenly. This should only be done with medical advice, as uncontrolled seizures or untreated illness can also carry serious risks. Current UK guidance states that valproate must only be used under strict safety conditions where pregnancy is possible.
Fetal Valproate Spectrum Disorder, often shortened to FVSD, describes a range of physical, developmental, neurological, emotional and learning difficulties that may affect a child following exposure to valproate medicines during pregnancy.
Valproate medicines include sodium valproate and brands such as Epilim. Valproate can be an effective medicine for epilepsy and some other conditions, but exposure during pregnancy is known to carry serious risks for the developing baby. UK Government guidance states that around 1 in 9 babies exposed to valproate in pregnancy may have a birth defect, and many may experience developmental or learning difficulties as they grow.